Date |
Product |
Disease |
Phase |
Company |
Therapeutic area |
2011-01-11
|
biosimilar rituximab |
rheumatoid arthritis |
2 |
Sandoz (Switzerland) |
Autoimmune diseases – Inflammatory diseases - Rheumatic diseases |
2011-01-10
|
BC-3781 |
acute bacterial skin and skin structure infections (ABSSSI) |
2 |
Nabriva Therapeutics (Austria) |
Infectious diseases |
2011-01-07
|
4SC-203 |
|
1 |
4SC (Germany) |
Cancer Oncology |
2011-01-03
|
Nalmefene |
alcohol dependence |
3 |
Lundbeck (Denmark) |
CNS diseases |
2010-11-22
|
SYL040012 |
ocular hypertension., glaucoma |
1-2 |
Sylentis (Spain) |
Ophtalmological diseases |
2010-11-01
|
galunisertib (LY2157299) |
hepatocellular carcinoma |
2 |
Eli Lilly (USA - IN) |
Cancer - Oncology |
2010-10-12
|
galunisertib |
glioma |
1b-2a |
Eli Lilly (USA - IN) |
Cancer - Oncology |
2008-03-05
|
aglatimagene besadenovec (AdV-tk) followed by valacyclovir |
glioma |
1 |
Advantagene (USA - MA) |
Cancer - Oncology |
2007-12-27
|
aglatimagene besadenovec (AdV-tk) followed by valacyclovir |
glioma |
2a |
Advantagene (USA - MA) |
Cancer - Oncology |